Business context and reporting period
INmune Bio, Inc. filed this Form 10-K for the fiscal year ended December 31, 2022. The clinical-stage biotechnology company has no approved products and focuses on innate-immune therapies: INKmune for cancer, INB03 for cancer, and XPro for Alzheimer’s disease and treatment-resistant depression. The filing reports annual results, not standalone fourth-quarter results.
Key financial metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0.374 million | $0.181 million |
| Operating expenses | $26.325 million | $29.334 million |
| Research and development | $17.067 million | $20.543 million |
| General and administrative | $9.258 million | $8.791 million |
| Operating loss | $25.951 million | $29.153 million |
| Net loss | $27.299 million | $30.340 million |
| Net loss per share, basic and diluted | $1.52 | $1.88 |
| Net cash used in operating activities | $22.686 million | $28.504 million |
| Cash and cash equivalents at year-end | $52.153 million | $74.810 million |
| Working capital at year-end | $53.8 million | Not stated here |
| Debt at year-end | $15.0 million principal | $15.0 million principal |
Revenue came from mesenchymal stem-cell sales, not approved drugs. The company reported no meaningful product gross margin. It recorded $1.348 million of net other expense, including $2.014 million of term-loan interest expense. Cash and cash equivalents included $51.058 million held in a money market fund.
Material changes versus the prior year
- Net loss narrowed by $3.041 million, while operating cash use fell by $5.818 million.
- R&D expense declined $3.476 million, principally due to lower DN-TNF manufacturing costs and reduced COVID-19 trial spending; increased compensation partly offset the reduction.
- G&A expense rose $0.467 million, including higher compensation and stock-based compensation, partly offset by lower consulting costs.
- Revenue increased $0.193 million but remained immaterial relative to operating costs. Cash declined $22.657 million during 2022; financing cash flow was only $0.729 million, compared with $96.357 million in 2021, when the company raised substantial equity and debt financing.
- Stock-based compensation increased to $7.149 million from $4.796 million.
Liquidity, debt, outlook, and risks
- Management said year-end cash should fund operations for at least 12 months after the March 2, 2023 filing date, while cautioning that continuing development will require substantial additional financing. The company expects continued losses and cash use and does not expect products to be commercially available for several years, if ever.
- The $15 million secured term loan carried a 12.0% rate at December 31, 2022. Principal repayment was scheduled to begin in July 2023, with $5 million due in 2023 and $10 million in 2024; maturity is January 1, 2025. A 6.5% final payment fee also applies. The company disclosed 2022 non-financial covenant violations and said the lender waived them in February 2023.
- The FDA placed XPro’s U.S. program on full clinical hold in May 2022, citing product chemistry, manufacturing, and controls information. Phase II Alzheimer’s trials were proceeding in Australia and Canada, but U.S. enrollment depended on resolving the hold; the company could not predict when it would be lifted.
- Management planned a randomized Phase II trial of XPro in early Alzheimer’s disease, with a stated target of approximately 200 patients and a six-month treatment period. Its Phase II treatment-resistant depression trial remained in design and regulatory discussions; the company reported a $2.9 million NIH/NIMH award, with no grant proceeds received by year-end 2022.
- Management described plans to advance INKmune’s MDS study and pursue a solid-tumor trial, and to develop INB03 in combination cancer therapy. These are development plans, not established clinical or financial guidance. Early XPro and INKmune findings included small, open-label or limited-patient data; the filing notes that such findings do not establish clinical benefit.
- Major risks include clinical-trial failure or delay, regulatory action, financing needs and dilution, debt service and covenants, dependence on third-party manufacturers and clinical sites, competition, intellectual-property protection, and uncertain reimbursement. Foreign-exchange movements affected comprehensive loss by $0.7 million in 2022.
- After year-end, the company received approximately $2.710 million of UK and $3.763 million of Australian R&D tax-credit reimbursements in January and February 2023, respectively. It reported no material litigation. The auditor issued an unqualified opinion on the financial statements; management concluded disclosure controls and internal control over financial reporting were effective, and the auditor was not required to attest to internal-control effectiveness.
Important facts for investors to verify
- Whether the FDA lifts the XPro clinical hold, what additional comparability or manufacturing evidence is required, and the resulting U.S. trial timeline.
- Actual cash burn, timing and amount of R&D tax-credit receipts, and whether management’s stated cash runway remains adequate as trial and manufacturing costs evolve.
- Term-loan payment performance, the covenant waiver’s scope, and the high interest rate and final payment fee.
- Enrollment, safety, and efficacy results from XPro and INKmune trials, distinguishing preliminary observations from controlled, statistically persuasive outcomes.
- Potential dilution from financing needs and outstanding options: 4.841 million options were outstanding at year-end, in addition to 17.946 million common shares outstanding.
- Related-party arrangements, including the INKmune license from Immune Ventures, which is owned by company executives and directors, and payments to entities linked to company directors or officers.